Specialized Hospital For Active Treatment Of Hematological Diseases EAD

At the Specialized Hospital For Active Treatment Of Hematological Diseases EAD in Sofia, research is strongly focused on Hemic and Lymphatic Diseases and Neoplasms, especially blood cancers and marrow disorders. Trials are exploring new ways to treat acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndromes, myelofibrosis, and several forms of lymphoma.

• Evaluating new therapies and combinations for leukemia, lymphoma, and related blood cancers
• Studying treatment options for myelofibrosis and myelodysplastic syndrome to improve symptom control and disease response
• Assessing whether emerging approaches can extend survival and delay disease progression

This research area reflects a broad effort to improve outcomes for patients with difficult-to-treat hematologic malignancies and related bone marrow diseases.

The site also supports trials in Immune System Diseases, with studies involving conditions such as immune thrombocytopenia, antiphospholipid syndrome, Behçet’s syndrome, dermatomyositis, and immune-mediated necrotizing myopathy. These studies aim to better control abnormal immune activity and reduce disease-related complications.

• Testing new treatment approaches for immune-mediated disorders that affect blood cells, muscles, and connective tissues
• Exploring better ways to manage bleeding risk and immune-driven inflammation
• Building evidence on safety and effectiveness for patients with chronic autoimmune conditions

This part of the research portfolio highlights the hospital’s role in advancing care for complex immune conditions where standard treatment options may be limited.

A major focus at the hospital is Hemic and Lymphatic Diseases related to inherited bleeding disorders, including haemophilia A, hemophilia B, and inhibitor-related disease. Trials are examining ways to prevent bleeding episodes, improve clotting factor support, and support longer-term disease control.

• Studying new therapies for haemophilia A and hemophilia B, including patients with inhibitors
• Evaluating prevention of bleeding and reduction of bleeding frequency
• Assessing the safety and real-world usefulness of advanced replacement or gene-based treatments

This work is especially important for patients living with lifelong bleeding disorders who need more durable and convenient treatment options.

Clinical trials here also address myelodysplastic syndromes and other marrow failure states linked to anemia and transfusion dependence. Research is looking at therapies that may reduce the need for blood transfusions and improve hemoglobin levels in affected patients.

• Testing treatments for anemia in myelodysplastic syndromes and related marrow disorders
• Evaluating whether investigational therapies can reduce transfusion burden
• Focusing on supportive care approaches that may improve daily functioning and quality of life

These studies support a broader effort to strengthen care for patients whose blood disorders cause persistent fatigue, low counts, or repeated transfusion needs.

The site’s portfolio includes studies of targeted and extended-access treatments across Hemic and Lymphatic Diseases and Neoplasms. Research is examining whether newer medicines can improve disease control in patients with follicular lymphoma, marginal zone lymphoma, multiple myeloma, and CLL/SLL, while also collecting longer-term safety information.

• Comparing newer targeted therapies with established treatment options
• Following patients over time to understand durability of benefit and safety
• Supporting continued access to therapies for patients already benefiting from treatment

This area shows a strong emphasis on precision treatment strategies and long-term patient follow-up at the III Department of Clinical Hematology.